MARGARET ANDRZEJEWSKI PA-C
Prescription History 1578840468
Physician Assistant in Pittsburgh, PA


Quality Rating: 77.5 out of 100 score

NPI Status: Active since November 07, 2011

Contact Information

3471 5TH AVE
KAUFMANN MEDICAL BUILDING SUITE 916
PITTSBURGH, PA
ZIP 15213
Phone: (412) 647-4932

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MARGARET ANDRZEJEWSKI PA-C, an active Physician Assistant specialist practicing in Pittsburgh, PA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 12 documented patient claims. Among these therapy options, the most frequently utilized medication is Xifaxan, which accounts for 12 claims alone.

Medication Index

No matching medications currently found on file.

Xifaxan

Generic Formulation: RifaximinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
PA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply570
Conservative Utilization

This provider writes prescriptions for this formulation 47.8% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $37,327.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,110.64

State Avg Cost Per Claim

$2,573.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY.

Therapeutic Applications

This medication is used to treat diarrhea caused by the common bacteria known as E. coli (traveler's diarrhea). Rifaximin should not be used if you have a fever or bloody diarrhea. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. Rifaximin is also used to treat irritable bowel syndrome with diarrhea. It is also used to prevent a brain problem caused by liver disease (hepatic encephalopathy). It may help you think more clearly.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MARGARET ANDRZEJEWSKI PA-C provides transparency into local medical care patterns within Pittsburgh, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.